{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:38:16Z","timestamp":1783039096747,"version":"3.54.6"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005275","name":"Region Hovedstaden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R155-2013-16337"],"award-info":[{"award-number":["R155-2013-16337"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015756","name":"Cilag","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006442","name":"Det Sundhedsvidenskabelige Fakultet, K\u00f8benhavns Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006442","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001734","name":"K\u00f8benhavns Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.biopsych.2021.08.023","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T02:38:35Z","timestamp":1631068715000},"page":"236-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Dopaminergic Activity in Antipsychotic-Na\u00efve Patients Assessed With Positron Emission Tomography Before and After Partial Dopamine D2 Receptor Agonist Treatment: Association With Psychotic Symptoms and Treatment Response"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-7104","authenticated-orcid":false,"given":"Anne Korning","family":"Sigvard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette \u00d8degaard","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3756-7401","authenticated-orcid":false,"given":"Albert","family":"Gjedde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten Borup","family":"Bojesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Fugl\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Tangmose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1659-765X","authenticated-orcid":false,"given":"Yoshitaka","family":"Kumakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Helt\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn H.","family":"Ebdrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Thorbj\u00f8rn","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egill","family":"Rostrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birte Yding","family":"Glenth\u00f8j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2021.08.023_bib1","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III--the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2021.08.023_bib2","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","article-title":"The nature of dopamine dysfunction in schizophrenia and what this means for treatment","volume":"69","author":"Howes","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2021.08.023_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2019.07.008","article-title":"Heterogeneity of striatal dopamine function in schizophrenia: Meta-analysis of variance [published correction appears in Biol Psychiatry 2020;87:305]","volume":"87","author":"Brugger","year":"2020","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2021.08.023_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1192\/bjp.bp.113.138578","article-title":"A\u00a0neurobiological hypothesis for the classification of schizophrenia: Type a (hyperdopaminergic) and type b (normodopaminergic)","volume":"205","author":"Howes","year":"2014","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2021.08.023_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","article-title":"Schizophrenia, dopamine and the striatum: From biology to symptoms","volume":"42","author":"Mccutcheon","year":"2019","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.biopsych.2021.08.023_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/schbul\/sbr111","article-title":"Striatal presynaptic dopamine in schizophrenia, Part I: Meta-analysis of dopamine active transporter (DAT) density","volume":"39","author":"Fusar-Poli","year":"2013","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2021.08.023_bib7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2021.08.023_bib8","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","article-title":"Antipsychotic drug doses and neuroleptic\/dopamine receptors","volume":"261","author":"Seeman","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2021.08.023_bib9","doi-asserted-by":"crossref","first-page":"107704","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2021.08.023_bib10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0006-3223(99)00109-2","article-title":"Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET","volume":"46","author":"Lindstr\u00f6m","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2021.08.023_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0920-9964(98)00113-3","article-title":"Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia","volume":"35","author":"Hietala","year":"1999","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2021.08.023_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/archpsyc.61.2.134","article-title":"Presynaptic dopaminergic dysfunction in schizophrenia: A positron emission tomographic [18F]fluorodopa study","volume":"61","author":"McGowan","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2021.08.023_bib13","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/s41386-020-0740-x","article-title":"The role of dopamine dysregulation and evidence for the transdiagnostic nature of elevated dopamine synthesis in psychosis: A positron emission tomography (PET) study comparing schizophrenia, delusional disorder, and other psychotic disorders","volume":"45","author":"Cheng","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2021.08.023_bib14","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0140-6736(95)91801-9","article-title":"Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients","volume":"346","author":"Hietala","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2021.08.023_bib15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0920-9964(96)00102-8","article-title":"Presynaptic dopaminergic function in the striatum of schizophrenic patients","volume":"23","author":"Dao-Castellana","year":"1997","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2021.08.023_bib16","doi-asserted-by":"crossref","first-page":"8080","DOI":"10.1523\/JNEUROSCI.0805-07.2007","article-title":"Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: An [18F]fluorodopa\/positron emission tomography study","volume":"27","author":"Kumakura","year":"2007","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2021.08.023_bib17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.schres.2008.11.006","article-title":"Regional dopamine synthesis in patients with schizophrenia using L-[\u03b2-11C]DOPA PET","volume":"108","author":"Nozaki","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2021.08.023_bib18","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/schbul\/sbaa055","article-title":"Striatal dopamine and reward prediction error signaling in unmedicated schizophrenia patients","volume":"46","author":"Katthagen","year":"2020","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2021.08.023_bib19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/schbul\/sbaa128","article-title":"Dopamine and glutamate in antipsychotic-responsive compared with antipsychotic-nonresponsive psychosis: A multicenter positron emission tomography and magnetic resonance spectroscopy study (Strata)","volume":"47","author":"Egerton","year":"2021","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2021.08.023_bib20","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1073\/pnas.97.14.8104","article-title":"Increased baseline occupancy of D2 receptors by dopamine in schizophrenia","volume":"97","author":"Abi-Dargham","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2021.08.023_bib21","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","article-title":"Dopamine synthesis capacity in patients with treatment-resistant schizophrenia","volume":"169","author":"Demjaha","year":"2012","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2021.08.023_bib22","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.biopsych.2013.06.011","article-title":"Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function","volume":"75","author":"Demjaha","year":"2014","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2021.08.023_bib23","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/npp.2016.258","article-title":"Presynaptic dopamine capacity in patients with treatment-resistant schizophrenia taking clozapine: An [18F]DOPA PET study","volume":"42","author":"Kim","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2021.08.023_bib24","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/s41380-018-0042-4","article-title":"Determinants of treatment response in first-episode psychosis: An 18F-DOPA PET study","volume":"24","author":"Jauhar","year":"2019","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2021.08.023_bib25","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/brain\/awz093","article-title":"Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms","volume":"142","author":"Avram","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.biopsych.2021.08.023_bib26","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/schbul\/sbu220","article-title":"Striatal D(2\/3) binding potential values in drug-na\u00efve first-episode schizophrenia patients correlate with treatment outcome","volume":"41","author":"Wulff","year":"2015","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2021.08.023_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyw006","article-title":"Frontal D2\/3 receptor availability in schizophrenia patients before and after their first antipsychotic treatment: Relation to cognitive functions and psychopathology","volume":"19","author":"N\u00f8rbak-Emig","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2021.08.023_bib28","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1073\/pnas.91.24.11651","article-title":"Elevated dopa decarboxylase activity in living brain of patients with psychosis","volume":"91","author":"Reith","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2021.08.023_bib29","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/schbul\/sbx180","article-title":"Defining thelocus of dopaminergic dysfunction in schizophrenia: A meta-analysis and test of the mesolimbic hypothesis","volume":"44","author":"McCutcheon","year":"2018","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2021.08.023_bib30","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1017\/S0033291718004099","article-title":"The relation between dopamine D2 receptor blockade and the brain reward system: A longitudinal study of first-episode schizophrenia patients","volume":"50","author":"Wulff","year":"2020","journal-title":"Psychol Med"},{"key":"10.1016\/j.biopsych.2021.08.023_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/archgenpsychiatry.2010.10","article-title":"Increased synaptic dopamine function in associative regions of the striatum in schizophrenia","volume":"67","author":"Kegeles","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2021.08.023_bib32","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1054-3589(08)60849-2","article-title":"The modulation of corticoaccumbens transmission by limbic afferents and dopamine: A model for the pathophysiology of schizophrenia","volume":"42","author":"Grace","year":"1997","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.biopsych.2021.08.023_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0006-3223(99)00078-5","article-title":"The regulation of forebrain dopamine transmission: Relevance to the pathophysiology and psychopathology of schizophrenia","volume":"46","author":"Moore","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2021.08.023_bib34","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0165-0173(99)00049-1","article-title":"Gating of information flow within the limbic system and the pathophysiology of schizophrenia","volume":"31","author":"Grace","year":"2000","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.biopsych.2021.08.023_bib35","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/sj.npp.1300103","article-title":"Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in\u00a0vivo","volume":"28","author":"Gr\u00fcnder","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2021.08.023_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biopsych.2018.07.003","article-title":"The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: A positron emission tomography study","volume":"85","author":"Jauhar","year":"2019","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2021.08.023_bib37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/jcbfm.1993.7","article-title":"Human striatal L-DOPA decarboxylase activity estimated in\u00a0vivo using 6- [18F]fluoro-DOPA and positron emission tomography: Error analysis and application to normal subjects","volume":"13","author":"Kuwabara","year":"1993","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2021.08.023_bib38","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/0006-8993(70)90489-0","article-title":"Occurrence and distribution of L-DOPA decarboxylase in the human brain","volume":"22","author":"Lloyd","year":"1970","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2021.08.023_bib39","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0165-0173(82)90018-2","article-title":"Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in\u00a0vivo: A re-examination","volume":"257","author":"Gjedde","year":"1982","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2021.08.023_bib40","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/jcbfm.1985.87","article-title":"Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations","volume":"5","author":"Patlak","year":"1985","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2021.08.023_bib41","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/1073858409338217","article-title":"PET studies of cerebral levodopa metabolism: A review of clinical findings and modeling approaches","volume":"15","author":"Kumakura","year":"2009","journal-title":"Neuroscientist"},{"key":"10.1016\/j.biopsych.2021.08.023_bib42","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.jcbfm.9600079","article-title":"PET studies of net blood-brain clearance of FDOPA to human brain: Age-dependent decline of [18F]fluorodopamine storage capacity","volume":"25","author":"Kumakura","year":"2005","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2021.08.023_bib43","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/jcbfm.1991.155","article-title":"Kinetics and modeling of L-6-[18F]fluoro-DOPA in human positron emission tomographic studies","volume":"11","author":"Huang","year":"1991","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2021.08.023_bib44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/jcbfm.1993.8","article-title":"6-[18F]fluoro-l-DOPA metabolism in living human brain: A comparison of six analytical methods","volume":"13","author":"Hoshi","year":"1993","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2021.08.023_bib45","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1073\/pnas.88.7.2721","article-title":"Dopa decarboxylase activity of the living human brain","volume":"88","author":"Gjedde","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2021.08.023_bib46","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1017\/S0033291719002277","article-title":"Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-na\u00efve patients with psychosis","volume":"50","author":"Bojesen","year":"2020","journal-title":"Psychol Med"},{"key":"10.1016\/j.biopsych.2021.08.023_bib47","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.biopsych.2020.06.027","article-title":"Associations between cognitive function and levels of glutamatergic metabolites and gamma-aminobutyric acid in antipsychotic-na\u00efve patients with schizophrenia or psychosis","volume":"89","author":"Bojesen","year":"2021","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2021.08.023_bib48","first-page":"444","article-title":"Patterns of cortical structures and cognition in antipsychotic-na\u00efve patients with first-episode schizophrenia: A partial least squares correlation analysis","volume":"4","author":"Jessen","year":"2019","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"10.1016\/j.biopsych.2021.08.023_bib49","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1017\/S0033291720000409","article-title":"Differential effects of age at illness onset on verbal memory functions in antipsychotic-na\u00efve schizophrenia patients aged 12\u201343 years","volume":"51","author":"Fagerlund","year":"2021","journal-title":"Psychol Med"},{"key":"10.1016\/j.biopsych.2021.08.023_bib50","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archpsyc.1990.01810180089012","article-title":"SCAN. Schedules for clinical assessment in neuropsychiatry","volume":"47","author":"Wing","year":"1990","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2021.08.023_bib51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1192\/S0007125000297602","article-title":"Prediction of psychosis. A step towards indicated prevention of schizophrenia","volume":"172","author":"Yung","year":"1998","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1016\/j.biopsych.2021.08.023_bib52","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2021.08.023_bib53","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.neurobiolaging.2008.05.005","article-title":"Age-dependent decline of steady state dopamine storage capacity of human brain: An FDOPA PET study","volume":"31","author":"Kumakura","year":"2010","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.biopsych.2021.08.023_bib54","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1111\/j.1471-4159.1981.tb00587.x","article-title":"High- and low-affinity transport of D-glucose from blood to brain","volume":"36","author":"Gjedde","year":"1981","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.biopsych.2021.08.023_bib55","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0165-0270(97)00094-0","article-title":"On the accuracy of an [18F]FDOPA compartmental model: Evidence for vesicular storage of [18F]fluorodopamine in\u00a0vivo","volume":"76","author":"Deep","year":"1997","journal-title":"J\u00a0Neurosci Methods"},{"key":"10.1016\/j.biopsych.2021.08.023_bib56","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.biopsych.2006.01.010","article-title":"Frontal dopamine D(2\/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender","volume":"60","author":"Glenthoj","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2021.08.023_bib57","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ana.410380220","article-title":"Striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: Disparity between postmortem and positron emission tomography studies?","volume":"38","author":"Kish","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.biopsych.2021.08.023_bib58","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1176\/appi.ajp.157.4.632","article-title":"High levels of dopamine activity in the basal ganglia of cigarette smokers","volume":"157","author":"Salokangas","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2021.08.023_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0306-4522(91)90196-U","article-title":"Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia","volume":"41","author":"Grace","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2021.08.023_bib60","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/archgenpsychiatry.2012.847","article-title":"Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia","volume":"69","author":"Nielsen","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2021.08.023_bib61","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamapsychiatry.2017.2943","article-title":"A\u00a0test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia","volume":"74","author":"Jauhar","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2021.08.023_bib62","doi-asserted-by":"crossref","first-page":"e1087","DOI":"10.1038\/tp.2017.59","article-title":"Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology","volume":"7","author":"Bak","year":"2017","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2021.08.023_bib63","doi-asserted-by":"crossref","first-page":"e46488","DOI":"10.1371\/journal.pone.0046488","article-title":"Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[\u03b2-11C]DOPA","volume":"7","author":"Ito","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopsych.2021.08.023_bib64","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2215-0366(18)30268-2","article-title":"The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: A cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study [published correction appears in Lancet Psychiatry 2018;5:e28]","volume":"5","author":"Jauhar","year":"2018","journal-title":"Lancet Psychiatry"}],"updated-by":[{"DOI":"10.1016\/j.biopsych.2022.04.015","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000}}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322321015687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322321015687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T21:28:51Z","timestamp":1777411731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322321015687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0006322321015687"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2021.08.023","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dopaminergic Activity in Antipsychotic-Na\u00efve Patients Assessed With Positron Emission Tomography Before and After Partial Dopamine D2 Receptor Agonist Treatment: Association With Psychotic Symptoms and Treatment Response","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2021.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}